---
created: '2026-02-13T14:58:20.177958Z'
description: '...'
dg-home: false
dg-publish: true
gardenUsername: dev_admin
permalink: /garden/dev_admin/gene/esr1/
slug: esr1
tags:
- gene
- endocrine
- cancer_biology
- nuclear_receptor
- imported
- primekg
templateEngineOverride: njk
title: ESR1
type: gene
updated: '2026-02-13T14:58:20.177958Z'
---

{% raw %}
<h1>&quot;ESR1&quot;</h1>
<h2>Overview</h2>
<p>The <strong>ESR1</strong> gene encodes <strong>Estrogen Receptor Alpha (ERα)</strong>, a ligand-activated transcription factor belonging to the nuclear hormone receptor superfamily. It is the primary mediator of estrogen signaling in the breast, uterus, and pituitary gland.</p>
<p>Upon binding estrogen (Estradiol), ERα undergoes a conformational change, dimerizes, and translocates to the nucleus where it binds to Estrogen Response Elements (EREs) in DNA to regulate gene expression.</p>
<h2>Biological Functions</h2>
<h3>1. Reproductive Physiology</h3>
<ul>
<li><strong>Growth &amp; Development:</strong> Essential for the development of secondary sexual characteristics, breast tissue, and uterine lining proliferation.</li>
<li><strong>HPG Axis:</strong> Regulates the feedback loop with the pituitary (LH/FSH secretion).</li>
</ul>
<h3>2. Systemic Effects</h3>
<ul>
<li><strong>Bone:</strong> Maintains bone density by inhibiting osteoclasts.</li>
<li><strong>Cardiovascular:</strong> Mediates the cardioprotective effects of estrogen (vasodilation, lipid profile).</li>
</ul>
<h2>Clinical Significance</h2>
<ul>
<li><strong>Breast Cancer:</strong> ERα is overexpressed in ~70% of breast cancers (ER-positive). It drives tumor growth by activating proliferation genes.
<ul>
<li><strong>Endocrine Therapy:</strong> These cancers are treated with drugs that target ERα, either by blocking it (Tamoxifen) or degrading it (Fulvestrant), or by blocking estrogen synthesis (Aromatase Inhibitors).</li>
</ul>
</li>
<li><strong>Therapy Resistance:</strong> ESR1 mutations (e.g., Y537S, D538G) often emerge in metastatic breast cancer after Aromatase Inhibitor treatment. These mutations render the receptor constitutively active (always &quot;on&quot;) even without estrogen, leading to resistance.</li>
</ul>
<h2>Relationships</h2>
<p>ENCODES::<a class="internal-link is-unresolved" href="/404">Estrogen Receptor Alpha</a><br />
ACTIVATED_BY::<a class="internal-link is-unresolved" href="/404">Estrogen</a> - Primary ligand<br />
ACTIVATED_BY::<a href="/garden/dev_admin/labtest/estradiol/" class="internal-link">Estradiol</a> - High affinity ligand<br />
INHIBITED_BY::<a class="internal-link is-unresolved" href="/404">Tamoxifen</a> - SERM (Selective Estrogen Receptor Modulator)<br />
INHIBITED_BY::<a class="internal-link is-unresolved" href="/404">Fulvestrant</a> - SERD (Selective Estrogen Receptor Degrader)<br />
REGULATES::<a class="internal-link is-unresolved" href="/404">Gene Expression</a> - Via ERE binding<br />
ASSOCIATED_WITH_CONDITION::<a class="internal-link is-unresolved" href="/404">Breast Cancer</a> - ER+ subtype<br />
ASSOCIATED_WITH_CONDITION::<a href="/garden/dev_admin/condition/osteoporosis/" class="internal-link">Osteoporosis</a> - Loss of signaling causes bone loss<br />
INTERACTS_WITH::<a class="internal-link is-unresolved" href="/404">ESR2</a> - Estrogen Receptor Beta (can heterodimerize)<br />
INTERACTS_WITH::<a href="/garden/dev_admin/protein/ep300/" class="internal-link">EP300</a> - Co-activator<br />
INTERACTS_WITH::<a href="/garden/dev_admin/protein/src/" class="internal-link">SRC</a> - Co-activator (NCOA1)</p>
<h2>References</h2>
<ul>
<li>Green S, et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature. 1986;320(6058):134-9.</li>
<li>Robinson DR, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.</li>
</ul>

{% endraw %}